Firebrick Pharma is an Australian pharmaceutical developer, which was founded in 2012 by Dr Peter Molloy and Dr Stephen Goodall with the mission to develop a nasal spray that killed all the germs (viruses or bacteria) responsible for respiratory infections, such as the common cold. After 9 years of development and testing, our first product is now in the final stages of development and is called Nasodine® Nasal Spray*

Nasodine Nasal Spray contains the broad-spectrum antimicrobial agent, povidone-iodine. In clinical studies, Nasodine has been shown to be well-tolerated as a four-times-daily nasal spray. Patents have been filed worldwide on its use as a treatment and preventative for the common cold.

If approved, Nasodine will be a first-in-class nasal spray medicine that targets the cause of colds, where they start in the nose.

*Nasodine Nasal Spray is not yet approved for sale in Australia.

We encourage users of our LinkedIn page to read our Social Media and Website Usage Policy (available at www.firebrickpharma.com/social-media-and-website-usage-policy/) which sets out, among other things, your obligations when using our social media pages and websites.

Firebrick Pharma

Org chart

Teams

Offices